Holen Sie sich die Stockscreener-App
19.14
9.59%
-2.03
Handel nachbörslich:
21.64
2.50
+13.06%
Schlusskurs vom Vortag:
$21.17
Offen:
$21.02
24-Stunden-Volumen:
1.20M
Relative Volume:
2.00
Marktkapitalisierung:
$1.16B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-170.19M
KGV:
-6.4662
EPS:
-2.96
Netto-Cashflow:
$-154.68M
1W Leistung:
+20.45%
1M Leistung:
+18.29%
6M Leistung:
+60.44%
1J Leistung:
-29.68%
1-Tages-Spanne:
$19.03
$21.29
1-Wochen-Bereich:
$15.86
$21.51
52-Wochen-Spanne:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
19.14 | 1.28B | 688.00K | -170.19M | -154.68M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Why Spyre Therapeutics Inc. stock is a value investor pickWeekly Profit Report & AI Powered Market Trend Analysis - newser.com
Analyzing Spyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Stock Portfolio Risk Control - newser.com
How to integrate Spyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Is Spyre Therapeutics Inc. a candidate for recovery playWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Custom strategy builders for tracking Spyre Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Spyre Therapeutics' (SYRE) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 8.9%What's Next? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Published on: 2025-10-06 01:19:10 - newser.com
Spyre Therapeutics (SYRE) Highlights Progress at European Gastro - GuruFocus
Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress - Quiver Quantitative
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - The Manila Times
6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior - Stock Titan
Spyre Therapeutics Inc. stock volume spike explainedWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Tools to monitor Spyre Therapeutics Inc. recovery probability2025 Stock Rankings & Smart Money Movement Tracker - newser.com
Spyre Therapeutics Inc. stock daily chart insightsEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilientMarket Risk Analysis & AI Driven Price Predictions - newser.com
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
42,500 Stock Options — Spyre Therapeutics Grants Options at $16.46 to Three Non‑Executive Employees - Stock Titan
What Fibonacci levels say about Spyre Therapeutics Inc. reboundJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Will Spyre Therapeutics Inc. stock pay special dividends2025 Macro Impact & Real-Time Volume Analysis - newser.com
What candlestick patterns are forming on Spyre Therapeutics Inc.Trend Reversal & Weekly High Conviction Ideas - newser.com
Why millennials buy Spyre Therapeutics Inc. (3920) stockTrade Risk Report & Smart Swing Trading Techniques - newser.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $54.29 Average PT from Brokerages - Defense World
What analysts say about Spyre Therapeutics Inc 3920 stockStock Watchlist Updates & Low Risk Capital Growth - earlytimes.in
What technical charts say about Spyre Therapeutics Inc. stockJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Published on: 2025-09-29 23:52:21 - newser.com
Published on: 2025-09-29 23:49:14 - newser.com
Published on: 2025-09-29 13:35:29 - newser.com
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
Nov 06 '24 |
Sale |
36.76 |
6,700 |
246,313 |
27,360 |
| Albers Jeffrey W. | Director |
Oct 25 '24 |
Sale |
36.43 |
300 |
10,929 |
34,060 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):